Advertisement

Supportive Care in Cancer

, Volume 23, Issue 11, pp 3331–3339 | Cite as

Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

  • Yuka Matsuda
  • Kenji OkitaEmail author
  • Tomohisa Furuhata
  • Goro Kutomi
  • Kentaro Yamashita
  • Yasushi Sato
  • Rishu Takimoto
  • Koichi Hirata
Original Article

Abstract

Purpose

The Multinational Association of Supportive Care in Cancer (MASCC) developed the MASCC antiemesis tool (MAT) as a tool for chemotherapy-induced nausea and vomiting (CINV) assessment and subsequently published its Japanese version in 2010. We evaluated the validity of CINV assessment in outpatients using the Japanese version of MAT.

Methods

Patients administered highly or moderately emetogenic chemotherapy in the outpatient chemotherapy unit of our hospital were included in the study. The study was designed as a prospective two-period crossover observational study to evaluate the correlation between the daily patient diary and the Japanese version of MAT in terms of CINV onset. We examined with a focus on reliability of the Japanese version of MAT particularly in the description of the delayed phase of nausea and vomiting.

Results

Patient descriptions of CINV onset in a total of 116 cycles in 58 patients (two cycles/patient) were analyzed. The CINV incidence indicated by the patient diary was similar to that by the Japanese version of MAT. The concordance rate between the two tools in the same patients was 86.2 % for CINV onset in the delayed phase. The nausea score was also similar between the two tools regarding the mean and variance, showing a strong correlation with a correlation coefficient of 0.71.

Conclusions

The results of the study showed that the Japanese version of MAT is a highly reliable tool for CINV assessment, indicating that it is valid for assessing CINV in outpatients.

Keywords

Chemotherapy-induced nausea and vomiting MASCC antiemesis tool Antiemetics Symptom evaluation 

Notes

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH (1983) On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMedGoogle Scholar
  2. 2.
    Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH (1993) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189–195CrossRefGoogle Scholar
  3. 3.
    de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7:59–65CrossRefPubMedGoogle Scholar
  5. 5.
    Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155–163CrossRefPubMedGoogle Scholar
  6. 6.
    Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Rd W, Carides AD, Taylor A, Evans JK, Horqan KJ (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278–1285CrossRefPubMedGoogle Scholar
  7. 7.
    Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B (2011) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer 19:823–832CrossRefPubMedGoogle Scholar
  8. 8.
    Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla R (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    National Comprehensive Cancer Network: Antiemesis Guidelines version 1 (2014) http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
  10. 10.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198CrossRefPubMedGoogle Scholar
  11. 11.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243CrossRefGoogle Scholar
  12. 12.
    Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, on behalf of the PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992CrossRefPubMedGoogle Scholar
  13. 13.
    Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Suárez C, Zorrilla I, Gómez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer 20:3141–3148CrossRefPubMedGoogle Scholar
  14. 14.
    Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2012) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227CrossRefGoogle Scholar
  15. 15.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115–124CrossRefPubMedGoogle Scholar
  16. 16.
    Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol 29:1495–1501CrossRefPubMedGoogle Scholar
  17. 17.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMedGoogle Scholar
  18. 18.
    Majem M, Moreno ME, Calvo N, Feliu A, Pérez J, Mangues MA, Barnadas A (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983–1990CrossRefPubMedGoogle Scholar
  19. 19.
    Multinational Association of Supportive Care in Cancer: MASCC antiemesis tool Japanese. http://www.mascc.org/assets/documents/MAT_japanese_questionaire_2010.doc
  20. 20.
    Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34:148–159CrossRefGoogle Scholar
  21. 21.
    Rhodes VA, McDaniel RW (1999) The index of nausea, vomiting, and retching: a new format of the index of nausea and vomiting. Oncol Nurs Forum 26:889–894PubMedGoogle Scholar
  22. 22.
    National Cancer Institute: Patient-reported outcomes version of the CTCAE (PRO-CTCAE). https://wiki.nci.nih.gov/display/PROCTCAE/Patient-Reported_Outcomes_version_of_the_CTCAE_
  23. 23.
    Japan Society of Clinical Oncology (2010) JSCO guidelines for antiemetics in oncology 2010. Kanehara & Co., Ltd., TokyoGoogle Scholar
  24. 24.
    Morrow GR (1984) Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer 53:2267–2278CrossRefPubMedGoogle Scholar
  25. 25.
    Osoba D, Zee B, Pater J, Warr D, Latrielle J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:116–123PubMedGoogle Scholar
  26. 26.
    Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98:645–655CrossRefPubMedGoogle Scholar
  27. 27.
    Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340CrossRefPubMedGoogle Scholar
  28. 28.
    Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM (2003) Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39:1395–1401CrossRefPubMedGoogle Scholar
  29. 29.
    Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179–185CrossRefPubMedGoogle Scholar
  30. 30.
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Yuka Matsuda
    • 1
  • Kenji Okita
    • 2
    Email author
  • Tomohisa Furuhata
    • 2
  • Goro Kutomi
    • 2
  • Kentaro Yamashita
    • 3
  • Yasushi Sato
    • 4
  • Rishu Takimoto
    • 4
  • Koichi Hirata
    • 2
  1. 1.Department of Nursing, Outpatient Chemotherapy CenterSapporo Medical UniversitySapporoJapan
  2. 2.Department of Surgery, Surgical Oncology and ScienceSapporo Medical UniversitySapporoJapan
  3. 3.Department of Gastroenterology, Rheumatology and Clinical ImmunologySapporo Medical UniversitySapporoJapan
  4. 4.Department of Medical Oncology and HematologySapporo Medical UniversitySapporoJapan

Personalised recommendations